These are exposure studies associated with the chemical and all of its children.
|Reference||Associated Study Title||Author's Summary||Study Factors||Stressor||Receptors||Country||Medium||Exposure Marker||Measurements||Outcome|
|1.||O'Connor P, et al. (2016).||Teriflunomide Multiple Sclerosis Oral (TEMSO) Study||In the Teriflunomide Multiple Sclerosis Oral extension, safety observations were consistent with the core trial, with no new or unexpected adverse events in patients receiving teriflunomide for up to 9 years. Disease activity decreased in patients switching from placebo and remained low in patients continuing on teriflunomide.||teriflunomide||Subjects with disease:Multiple Sclerosis||Austria|Canada|